newest glp 1 agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care GLP-1 Receptor Agonist Market Forecast
Description
Exenatide extended-release (ER) , taken weekly: FDA-approved under the brand name Bydureon to treat type 2 diabetes
Cummings, J
doi: 10.1007/s00125-010-2028-x [DOI] [PubMed] [Google Scholar] 168
00197-4/asset/bc822c6e-5915-4cb3-97bc-7187c857a496/main.assets/gr1_lrg.jpg)
The FDA Adverse Event Reporting System (FAERS) contains reports of musculoskeletal complaints associated with GLP-1 use, but such reports do not prove causation and may reflect coincidental associations or other contributing factors
Fang, X
A very respectful firm.
